← Back to headlines
Gossamer Bio Downgraded by Cantor Due to Unclear Seralutinib Regulatory Path
Gossamer Bio has been downgraded by Cantor, citing an unclear regulatory path for its drug seralutinib as the reason for the revised outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
